| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Rosetta InPharmatics, Inc. |
| 12040 115th Avenue N.E., Kirkland, WA 98034 * (425) 820-8900 |
| Business Description | The company is a leader in the emerging field of informational genomics. Informational genomics involves acquiring and analyzing information gathered from throughout the cell to identify a majority of the medically important drug targets and gene functions. |
| Offering Information Company has | |||
| Trading As | RSTA (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 3/17/00 |
| Domestic Shares Offered | 7,200,000 | Offer Date | 8/2/00 |
| Foreign Shares Offered | 0 | Filing Range | $10.00 - $12.00 |
| Company Shares | 7,200,000 | Offer Price | $14.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.980 |
| Gross Proceeds | $100,800,000 | Selling | $0.580 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 29,030,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| Fidelity Capital Markets | Co-manager | |
| Lazard Freres & Co. | Co-manager | (212) 632-6717 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.983 | 0.292 | 0.548 |
| Income from Oper. | - | - | -2.293 | -7.693 | -20.083 | -3.271 | -8.448 |
| Net Income | - | - | -1.885 | -7.112 | -19.819 | -3.223 | -8.179 |
| E.P.S | - | - | -5.290 | -5.290 | -4.920 | -1.210 | -3.640 |
| Revenue Growth (%) | - | - | - | - | 87.67 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.41 | -1.90 | -4.00 | ||||
| Cash Flow - Inv. | -8.41 | 0.69 | 0.63 | ||||
| Cash Flow - Fin. | 20.86 | -0.15 | 41.57 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 80.23 | Current Assets | 56.17 | Current Ratio | 11.02 |
| Total Liab. | 9.76 | Current Liab. | 5.10 | Debt Ratio | 12.16% |
| Total Equity | 70.47 | Working Cap. | 51.08 | Debt to Equity Ratio | 0.14 |
| Cash | 46.51 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for continued research and development, including expanding our informational genomics platform to include other data types and analysis tools, to increase our marketing and sales efforts to support our products and services, including our Resolver system, for working capital and other general corporate purposes and capital expenditures. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Venture Law Group |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Registrar/Transfer Agent | Harris Trust Company of California |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Vulcan Ventures, Inc. | 16.40 | |
| Agilent Technologies, Inc. | 12.70 | |
| Olympic Venture Partners | 7.20 | |
| Lombard Odier & Cie | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||